| First Author | Sheng YH | Year | 2019 |
| Journal | Oncogene | Volume | 38 |
| Issue | 48 | Pages | 7294-7310 |
| PubMed ID | 31427737 | Mgi Jnum | J:298288 |
| Mgi Id | MGI:6477467 | Doi | 10.1038/s41388-019-0951-y |
| Citation | Sheng YH, et al. (2019) MUC13 promotes the development of colitis-associated colorectal tumors via beta-catenin activity. Oncogene 38(48):7294-7310 |
| abstractText | Many adenocarcinomas, including colorectal cancer (CRC), overexpress the MUC13 cell surface mucin, but the functional significance and mechanisms are unknown. Here, we report the roles of MUC13 in colonic tumorigenesis and tumor progression. High-MUC13 expression is associated with poor survival in two independent patient cohorts. In a comprehensive series of in vivo experiments, we identified a critical role for MUC13 in the development of this malignancy, by promoting survival and proliferation of tumor-initiating cells and driving an immunosuppressive environment that protects tumors from checkpoint inhibitor immunotherapy. In Muc13-deficient mice, fewer tumors are generated after exposure to carcinogens and inflammation, they have markedly reduced beta-catenin signaling, have more tumor-infiltrating CD103(+) dendritic cells and CD8(+) T lymphocytes, fewer myeloid-derived suppressor cells, and are rendered sensitive to checkpoint inhibitor immunotherapy (anti-PD-L1). Mechanistically, we show that MUC13 protects beta-catenin from degradation, by interacting with GSK-3beta, which increases beta-catenin nuclear translocation and promotes its signaling, thereby driving cancer initiation, progression, invasion, and immune suppression. Therefore, MUC13 is a potential marker of poor prognosis in colorectal cancer, and inhibiting MUC13 may be useful in the treatment of colitis-associated cancer and sensitizing tumors to immunotherapy. |
